Corcept's cortisol modulator fails to slow ALS decline

Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a phase 2 trial and was also linked to “substantially more gastrointestinal upset.”